Fulcrum Therapeutics Inc. (FULC)
3.70
+0.20 (5.71%)
Upcoming Events
Latest Headlines
Form 8-K Fulcrum Therapeutics, For: Jun 05
June 11, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
June 10, 2026 6:13 PM - SEC Filing
Form 8-K Fulcrum Therapeutics, For: May 31
June 4, 2026 4:05 PM - SEC Filing
Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (FULC)
June 2, 2026 4:26 PM - StreetInsider
JPMorgan Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
June 2, 2026 4:26 PM - StreetInsider
Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns
June 2, 2026 6:42 AM - StreetInsider
H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral
June 2, 2026 6:07 AM - StreetInsider
Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform
June 2, 2026 6:03 AM - StreetInsider
Piper Sandler Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
June 2, 2026 1:08 AM - StreetInsider
Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold
June 2, 2026 1:04 AM - StreetInsider
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
June 1, 2026 6:37 PM - StreetInsider
After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
June 1, 2026 4:37 PM - StreetInsider
Fulcrum Therapeutics discontinues pociredir program, begins strategic review
June 1, 2026 4:10 PM - StreetInsider
Form 8-K Fulcrum Therapeutics, For: Jun 01
June 1, 2026 4:07 PM - SEC Filing
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 1, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC
May 15, 2026 4:43 PM - SEC Filing
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: TCG Crossover GP II, LLC
May 15, 2026 4:33 PM - SEC Filing
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026 4:30 PM - StreetInsider
Form 4 Fulcrum Therapeutics, For: Apr 23 Filed by: Lehrer-Graiwer Joshua
May 1, 2026 4:16 PM - SEC Filing
Form 3 Fulcrum Therapeutics, For: Apr 23 Filed by: Lehrer-Graiwer Joshua
May 1, 2026 4:10 PM - SEC Filing
Form DEFA14A Fulcrum Therapeutics,
April 30, 2026 4:20 PM - SEC Filing
Form ARS Fulcrum Therapeutics, For: Dec 31
April 30, 2026 4:17 PM - SEC Filing
Form DEF 14A Fulcrum Therapeutics, For: Jun 24
April 30, 2026 4:12 PM - SEC Filing
Form 10-Q Fulcrum Therapeutics, For: Mar 31
April 27, 2026 7:11 AM - SEC Filing
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 5c
April 27, 2026 7:07 AM - StreetInsider
Form 8-K Fulcrum Therapeutics, For: Apr 23
April 27, 2026 7:05 AM - SEC Filing
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026 7:00 AM - Globe NewsWire
Fulcrum Therapeutics adds Josh Lehrer to board of directors
April 27, 2026 6:55 AM - StreetInsider
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026 6:55 AM - Globe NewsWire
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
April 20, 2026 8:00 AM - Globe NewsWire
Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'
March 31, 2026 1:08 PM - StreetInsider
Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'
March 31, 2026 8:54 AM - StreetInsider
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 6:38 PM - SEC Filing
Full Article List
